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INTRODUCTION
Breast cancer is one of the most prevalent cancers and its 
incidence is further increasing, causing a major concern for 
women’s health. Various modalities have been tried and the 
mortality rate is decreasing with medical advances. However, 
outcomes in breast cancer patients are variable even in the pa-
tients in same stage. To individualize treatment and to predict 
outcomes, novel biomarkers that will lead to molecular diag-
nostic tests are required.
MicroRNAs (miRNAs), small non-coding endogenous RNA 
gene products consisting of 18 to 25 nucleotides, were first dis-
covered in 1993 [1]. After a multistage process commencing 
in the nucleus, pri-mRNAs are trimmed into pre-mRNAs and 
are exported to the cytoplasm. Following cleavage by the endori-
bonuclease dicer, pre-miRNAs are converted into mature miRNAs 
that are incorporated into the RNA-induced silencing com-
plex (miRISC) and target messenger RNA (mRNA), resulting 
in cleavage or translational repression. By targeting mRNAs, 
miRNAs play critical roles in cell proliferation, differentiation, 
and apoptosis and, moreover, can act as tumor suppressors or 
oncogenes [2-6].
Iorio et al. [7] first reported 29 miRNAs associated with breast 
cancer and many more have since been discovered. Among 
these miRNAs, miR-21 is known to be overexpressed in breast 
cancer [7-10]. Studies have demonstrated that miR-21 functions 
as an oncogene by targeting tumor suppressor genes including 
tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4), 
and phosphatase and tensin homolog (PTEN), leading to cell 
proliferation and inhibition of apoptosis and regulating cancer 
invasion and metastasis in breast cancer [11-13].
There has been a recent increase in studies involving miR-21, 
some of which propose that miR-21 is related to breast cancer 
patients’ prognosis while others give opposing results [9-13]. 
To use miR-21 as a novel biomarker in breast cancer, its clini-
cal relevance should be verified. This study was performed to 
understand the biological role of miR-21 expression in breast 
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Purpose: Among more than 500 microRNAs, microRNA-21   
(miR-21) is known to act as an oncogene. The aim of this study 
was to investigate the significance of miR-21 expression level in 
relation with clinicopathological factors and prognosis in breast 
cancer. Methods: MicroRNA was extracted from cancer and nor-
mal breast tissue of 109 breast cancer patients who underwent 
surgery from 2002 to 2004 using the Taqman
® MicroRNA Assay. 
The correlation between miR-21 expression and clinicopathologic 
features was analyzed and the significance of miR-21 as a prog-
nostic factor and its relationship with survival was determined. 
Results: MiR-21 expression was higher in cancer tissues than in 
normal tissues (p<0.0001). High miR-21 expression was associ-
ated with mastectomy, larger tumor size, higher stage, higher grade, 
estrogen receptor (ER) negative, human epidermal growth factor 
receptor 2 (HER2) positive, HER2 positive breast cancer subtype, 
high Ki-67 expression, and death. On multivariate analysis, prog-
nostic factors for overall survival were ER and miR-21. High miR-
21 expression was significantly related to lower overall survival 
(p=0.031). Conclusion: This study supports the role of miR-21 as 
an oncogene and a biomarker for breast cancer with its high expres-
sion in cancer tissues and its relationship with other prognostic 
factors and survival.
Key Words: Breast neoplasms, Human MicroRNA-21, Oncogene, Prognosis, 
Survival
Correspondence:  Jeoung Won Bae
Department of Surgery, Korea University Anam Hospital, Korea University 
College of Medicine, 126-1 Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, 
Korea
Tel: +82-2-920-5305, Fax: +82-2-928-1631
E-mail: kujwbae@korea.ac.kr
The present research has been supported by Korea Breast Cancer Foundation 
and Korea University Grant.
Received: July 14, 2011  Accepted: September 30, 2011
Journal of
        Breast
Cancer270  JungAhLee,etal.
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2011.14.4.269
cancer by investigating the relationship between the expression 
of miR-21 and clinicopathological characteristics and survival 
in breast cancer patients. 
METHODS
Materials
We collected clinical and pathologic reports of patients with 
invasive ductal breast cancer in stage I to III who underwent 
surgery between January 2002 and December 2004 in Korea 
University Anam Hospital. Among 252 patients, two patients 
had synchronous cancer in other organs, seven received neo-
adjuvant therapies, 15 had no follow up data, 13 had insufficient 
tumor or normal tissue, 16 had incomplete pathologic report, 
81 lacked slides, and nine had ΔCT>30; these patients were 
excluded from this study. Age was divided into two groups, 
under and over 50 years old. Patients were treated with either 
breast conserving surgery or total mastectomy. As for axillary 
dissection, patients who were not clinically suspected to have 
metastasis went through sentinel lymph node biopsy and if 
proven positive, axillary dissection was done. For those who 
were confirmed to have axillary metastasis from biopsy, axil-
lary dissection was performed. The cut-off value for tumor size 
was 2 cm and lymph node status was defined as positive if there 
was metastasis. Clinical stage was classified according to the 7th 
American Joint Committee on Cancer (AJCC) classification [14]. 
Grade was evaluated using the Bloom and Richardson cri-
teria suggested by the Nottingham City Hospital Pathologists. 
Assessment of estrogen receptor (ER) and progesterone recep-
tor (PR) status was performed by standard immunohistochem-
ical methods and considered positive if the value was >10% of 
nuclear staining. For human epidermal growth factor receptor 
2 (HER2) status, 0 and 1+ were considered as negative and 3+ 
as positive. HER2 status 2+, which was one case, was not in-
cluded in statistical analysis. Subtypes were divided according 
to ER, PR, and HER2 status as follows: luminal A (ER+ and/
or PR+, HER2-), luminal B (ER+ and/or PR+ HER2+), HER2+ 
(ER-, PR-, HER2+), and triple negative breast cancer (TNBC; 
ER-, PR-, HER2-). The p53 cut-off value was 10% and Ki-67 
expression of <20% was considered low expression. Patholog-
ical analyses, including identification of tumor and normal 
tissues, were performed by one pathologist. If there were ques-
tionable or missing data, the analysis was repeated. This study 
was approved by the Institutional Review Board of Korea Uni-
versity Anam Hospital (IRB No AN10050-002). 
Methods
Using a microtome, 10 μm slices of formalin-fixed, paraffin-
embedded tissue were obtained and placed in 1.5 mL micro-
centrifuge tubes. To isolate RNA, 0.75 mL TRI Reagent
® (Applied 
Biosystems, Foster City, USA) was added, followed by incuba-
tion at room temperature for 5 minutes. After addition of 0.2 
mL chloroform and thorough mixing, the sample was centri-
fuged for 10 minutes at 14,000 rpm and the clear supernatant 
was transferred into new tubes. After adding 0.5 mL isopro-
panol and mixing well, the samples were stored for 2 hours at 
-20°C and centrifuged for 15 minutes (14,000 rpm) at 4°C. 
The supernatant was removed without disturbing the pellet, 
and 1 mL 70% ice-cold ethanol was added to the pellet and   
re-centrifuged, again discarding the supernatant. The final pellet 
was dissolved in 50 μL DEPC-DW and RNA yield was deter-
mined using a UV spectrophotometer. Amounts of 0.5-1 μg 
were used in a reverse transcriptase reaction. After reverse 
transcription, a TaqMan
® MicroRNA Assay (Applied Biosys-
tems) was performed according to the manufacturer’s protocol 
to detect miR-21 expression using Applied Biosystems using 
miR-21 as a primer (Assay ID: 000397) and small nRNA, 
RNU6 (Assay ID: 001093) as a control. 
∆
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Expression of miR-21 was analyzed by relative quantity (RQ) 
using the equation RQ=2¯ΔΔ
CT (CT=threshold cycle to detect 
fluorescence). According to the definition of CT, lower value 
is consistent with faster detection of fluorescent which is due 
to higher expression of miR-21as shown in Figure 1A. ΔΔCT is 
defined as the difference in miR-21 expression between tumor 
and normal tissue [ΔΔCT=(CTmiRNA-21-CTU6 RNA)tumor-(CTmiRNA-21- 
CTU6 RNA)normal]. Each analysis was performed in duplicate by 
StepOne
TM Software v2.1 (Applied Biosystems, Foster City, 
USA) and samples with ΔCT>30 were excluded for accuracy. 
Statistical analysis
The relationship between miR-21 expression level and clini-
copathologic features of the patients was analyzed using the chi-
square test. Prognostic factors for breast cancer were examined 
by Cox proportional hazard regression model and survival 
curves were estimated by the Kaplan-Meier method. Statisti-
cal analysis was performed using SPSS version 13.0 software 
(SPSS Inc., Chicago, USA) and p-value <0.05 were considered 
significant. 
RESULTS
Patient characteristics
A total of 109 patients were analyzed in this study. The mean 
age was 48 years and 72 patients (66.1%) were under 50 years 
old. Sixty-eight patients (62.4%) had tumor size smaller than 
2 cm, and 62 (56.9%) had no lymph node metastasis. When 
classified into breast cancer subtypes, 60 patients (55.5%) were 
luminal A, 14 (13%) were luminal B, 27 (25%) were HER2+, 
and seven (6.5%) were TNBC. The mean RQ was 5.92±7.19, 
and 78 (71.6%) patients were classified as low miR-21 (≤5.92) 
and 31 (28.4%) as high miR-21 (>5.92). Local recurrence o 
ccurred in 2 patients, regional recurrence in 1 patient, distant 
metastasis in 17 patients and six patients died. Patients’ char-
acteristics are outlined in Table 1. The mean overall and dis-
ease-free survival times were 54 and 36 months, respectively. 
MiR-21 expression in breast cancer
We analyzed the miR-21 expression level in tumor and nor-
mal tissues acquired from the same breast cancer patients. 
The mean miR-21 expression level (ΔCT) was -7.044±1.26 for 
tumor tissue and -5.32±1.34 for normal breast tissue; this dif-
ference was statistically significant with a p-value of <0.0001 
(Figure 1B).
MiR-21 expression and clinicopathologic features of breast 
cancer patients
Table 2 shows the correlation between clinicopathologic 
features and miR-21 expression. High miR-21 expression was 
related to mastectomy (p=0.005) and tumor size >2 cm (p= 
Table 1. Patient characteristics
Characteristics No. of patients (%)
All patients 109 (100.0)
Age (yr)
   ≤50 72 (66.1)
   >50 37 (33.9)
Operation method
   Total mastectomy 61 (56.0)
   Breast conserving surgery 48 (44.0)
Tumor size (cm)
   ≤2 68 (62.4)
   >2 41 (37.6)
Lymph node status
   Negative  62 (56.9)
   Positive 47 (43.1)
Stage (TNM)
   I 45 (41.3)
   II 42 (38.5)
   III 22 (20.2)
Histologic grade
   1 25 (23.0)
   2 42 (38.5)
   3 42 (38.5)
Estrogen receptor status
   Negative 36 (33.0)
   Positive 73 (67.0)
Progesterone receptor status
   Negative 44 (40.4)
   Positive 65 (59.6)
HER2/neu expression
   Negative 67 (62.0)
   Positive 41 (38.0)
Breast cancer subtype
   Luminal A 60 (55.5)
   Luminal B 14 (13.0)
   HER2+ 27 (25.0)
   TNBC 7 (6.5)
Ki-67 expression
   <20% 37 (33.9)
   ≥20% 72 (66.1)
p53 
   Negative 69 (63.3)
   Positive 40 (36.7)
miR-21 RQ
   Low (≤5.92) 78 (71.6)
   High (>5.92) 31 (28.4)
Recurrence
   No 89 (81.7)
   Yes 20 (18.3)
Death
   No 103 (94.5)
   Yes 6 (5.5)
HER2=human epidermal growth factor receptor 2; TNBC=triple negative breast 
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0.047). Moreover, higher stage, higher grade, ER negativity, 
HER2 positivity, and high Ki-67 expression were significantly 
associated with high miR-21 expression. As hormone receptor 
(HR) status and HER2 expression is related to miR-21 expres-
sion level there was a substantially larger proportion of the 
HER2+ subtype (45.2%) in the high miR-21 expression group. 
However, no relationship was found between miRNA-21 expres-
sion and lymph node metastasis status and recurrence. High 
miR-21 expression level A was associated with a high death rate 
(p=0.034). 
Table 2. Correlation between miR-21expression and clinicopathologic 
factors
Characteristics
miR-21 RQ  
low (≤5.92)  
No. (%)
miR-21 RQ  
high (>5.92)  
No. (%)
p-value
Age (yr) 0.831
   ≤50 52 (66.7) 20 (64.5)
   >50 26 (33.3) 11 (35.5)
Operation method 0.005
   Total mastectomy 37 (47.4) 24 (77.4)
   Breast conserving surgery 41 (52.6) 7 (22.6)
Tumor size (cm) 0.047
   ≤2 53 (67.9) 15 (48.4)
   >2  25 (32.1) 16 (51.6)
Lymph node status  0.121
   Negative 48 (61.5) 14 (45.2)
   Positive 30 (38.5) 17 (54.8)
Stage 0.008
   I 39 (50.0) 6 (19.4)
   II 26 (33.3) 16 (51.6)
   III 13 (16.7) 9 (29.0)
Histologic grade 0.005
   1 22 (28.2) 3 (9.6)
   2 32 (41.0) 10 (32.3)
   3 24 (30.8) 18 (58.1)
Estrogen receptor status 0.002
   Negative 19 (24.4) 17 (54.8)
   Positive 59 (75.6) 14 (45.2)
Progesterone receptor status 0.053
   Negative 27 (34.6) 17 (54.8)
   Positive 51 (65.4) 14 (45.2)
HER2/neu expression 0.002
   Negative 55 (71.4) 12 (38.7)
   Positive 22 (28.6) 19 (61.3)
Breast cancer subtype 0.005
   Luminal A 50 (64.9) 10 (32.3)
   Luminal B 9 (11.7) 5 (16.1)
   HER2+ 13 (16.9) 14 (45.2)
   TNBC 5 (6.5) 2 (6.4)
Ki-67 expression 0.044
   <20% 31 (39.7) 6 (19.4)
   ≥20% 47 (60.3) 25 (80.6)
p53  0.784
   Negative 50 (64.1) 19 (61.3)
   Positive 28 (35.9) 12 (38.7)
Recurrence 0.531
   No 64 (82.1) 25 (80.6)
   Yes 14 (17.9) 6 (19.4)
Death 0.034
   No 76 (97.4) 27 (87.1)
   Yes 2 (2.6) 4 (12.9)
RQ=relative quantity; HER2=human epidermal growth factor receptor 2; 
TNBC=triple negative breast cancer. 
Table 3. Univariate analysis of prognostic factors associated with overall 
survival
Features
Univariate
HR 95% CI of HR p-value
Age (yr) 
   ≤50 vs. >50 0.980 0.179-5.349 0.981
Size (cm)
   ≤2 vs. >2 8.653 1.011-74.070 0.049
Lymph node status
   Negative vs. positive 1.312 0.265-6.503 0.738
Stage
   I and II vs. III 4.091 0.826-20.272 0.084
Histologic grade
   1 vs. 2 and 3 3.482 0.010-9.969 0.175
Estrogen receptor status
   Negative vs. positive 0.092 0.011-0.789 0.03
Progesterone receptor status
   Negative vs. positive 0.323 0.059-1.765 0.192
HER2/neu expression
   Negative vs. positive 1.824 0.151-4.497 0.822
Breast cancer subtype
   Luminal A vs. Luminal B 2.233 0.202-24.624 0.512 
   Luminal A vs. HER2 1.131 0.103-12.471 0.920
   Luminal A vs. TNBC 10.298 1.445-73.393 0.02
Ki-67 expression
   Negative vs. positive 2.573 0.301-22.021 0.388
p53
   Negative vs. positive 1.718 0.347-8.512 0.507
miR-21 RQ
   Low vs. high 5.316 0.973-29.026 0.054
CI=confidence interval; HR=hormone receptor; HER2=human epidermal 
growth factor receptor 2; TNBC=triple negative breast cancer; RQ=relative 
quantity. 
Table 4. Multivariate analysis of prognostic factors associated with over-
all survival
Features
Multivariate
HR 95% CI of HR p-value
Size (cm)
   ≤2 vs. >2 0.37
Estrogen receptor status
   Negative vs. positive 0.004 0.000-0.084 <0.001
miR-21 RQ
   Low vs. high 14.214   1.338-15.096 0.028
CI=confidence interval; HR=hormone receptor; RQ=relative quantity. MiR-21ExpressioninBreastCancer 273
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MiR-21 expression and prognosis and survival of breast cancer
On univariate analysis, factors associated with prognosis were 
tumor size (p=0.049) and ER status (p=0.03) (Table 3). For 
multivariate analysis, significant factors from univariate analysis 
and miR-21 expression were included. The prognostic signifi-
cance of miR-21 expression could not be ignored since the p-
value for high expression level was only slightly over 0.05 and 
the hazard ratio was 5.316. Multivariate analysis showed that 
high miR-21 expression and negative ER status were signifi-
cantly related to poor prognosis (Table 4). Lymph node metas-
tasis status, HER2 status, and proliferation rate (Ki-67 expres-
sion) were not associated with prognosis. On survival analysis, 
there were no significant differences in disease-free survival 
between low and high miR-21 expression level; however, over-
all survival was lower in the latter (Figure 2). 
DISCUSSION
The potential of miRNAs as novel biomarkers is growing     
as more studies report the relationship between miRNAs and 
cancers [5-7,15-17]: however, interest in miRNA begun only   
a few years ago and there are not many reports on miR-21 in 
breast cancers. Our study shows that miR-21 expression is signif-
icantly increased in breast cancer tissue and that higher expres-
sion is related to aggressive tumor characteristics. Moreover, 
breast cancer patients with high miR-21 expression seem to 
have a poor prognosis.
Consistent with our results, previous researchers have found 
that miR-21 is frequently overexpressed in breast cancer [8-11]. 
This is explained by its function as an oncogene, inhibiting   
tumor suppressor genes. By array expression analysis of MCF-
cells depleted of miR-21, Frankel et al. [12] reported a link     
between miR-21 and p53 tumor suppressor protein. Further-
more, their study showed that PDCD4 is directly regulated by 
miR-21. PDCD4 is a tumor suppressor gene that is downreg-
ulated in numerous human cancers and is known to function 
in the regulation of apoptosis [18]. Zhu et al. [13] searched for 
targets of miR-21 and found that TPM1 contains a putative 
miR-21 binding site and that regulation occurs at the transla-
tional level. They also demonstrated that overexpression of 
TPM1 suppresses cell growth in vitro [13]. Although the exact 
role of PTEN in breast cancer has not been elucidated, it has 
been found to be associated with tumor progression, acting as 
a tumor suppressor gene. Moreover, Huang et al. [11] proposed 
PTEN as a target gene of miRNA-21, suggesting that its expres-
sion is reduced by miR-21 in breast cancer. 
We confirmed the clinical importance of miR-21 expression 
by showing its association with unfavorable clinicopathologic 
features. Higher expression of miR-21 leads to increased inhi-
bition of tumor suppressor genes, resulting in increased tumor 
cell proliferation and inhibition of apoptosis; this explains the 
results of our study including its correlation with the prolifera-
tion marker Ki-67. However, axillary lymph node metastasis, 
which is one of the most important prognostic factors for breast 
cancer and recurrence, was not related to high miR-21 expres-
sion. This might be explained by the small population of this 
study. Even though there was no statistical significance, the 
proportion of patients with high miR-21 expression was 54.8% 
in those who had axillary lymph node metastasis which was 
higher than those who did not have metastasis (38.5%). If more 
patients were included, significant results might have been 
obtained. Furthermore, since invasion and metastasis including 
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axillary metastasis could not be explained by one mechanism 
but by regulation of interconnected molecular pathways or other 
undiscovered factors, this is just the beginning of the search 
for the role of miR-21. In a similar study by Yan et al. [10] with 
113 patients, only stage and lymph node status were related to 
high levels of miR-21. They explained this result by suggesting 
that up-regulation of miR-21 developed during tumor progres-
sion and acquisition of metastatic potential. On the other hand, 
in a larger study of 344 patients, Qian et al. [9] analyzed miR-21 
expression in fresh frozen tissues and did not find a relation-
ship with clinicopathologic features other than grade, histologic 
type, and ER status.
HR and HER2 status plays an important role in the manage-
ment and current classification of breast cancers [19-21]. There 
are numerous studies on molecular breast cancer subtypes, 
which are clinically divided into luminal A, luminal B, HER2+, 
and TNBC. HER2+ and TNBC types are reported to have poor 
prognosis due to the lack of targeting therapy and the biology 
of the tumor itself [22,23]. In this study it is likely that poor 
prognosis was related to HR negativity, which is linked to high 
miR-21 expression. Moreover, the high miR-21 group contained 
more patients with positive HER2 expression, which is known 
to have aggressive biology even though there is a targeting treat-
ment, suggesting that patients with high miR-21 expression 
will have a poorer outcome. However, there are no consistent 
reports and no known mechanisms for these relationships and 
one can only propose that miR-21 might affect related path-
ways regulating ER and HER2 status or a common mRNA 
target. To clarify these mechanisms, further research seems to 
be necessary. Because of the importance of molecular profiling 
and identification of intrinsic subtypes, Lowery et al. [24] per-
formed a study using artificial neural networks and concluded 
that miRNA could not only predict ER, PR, and HER2 status, 
but showed a superior accuracy over mRNA signatures in classi-
fying subtypes. 
Currently, mRNA molecular profiling of breast cancer is 
used commercially but faces problems regarding the accuracy 
of classical computational analysis, interference from inherent 
noise, the need for fresh frozen tissues, and overseas diagnosis, 
and for these reasons researchers are trying to find a universal, 
reproducible, and effective test to predict outcome and thera-
peutic response [17,24]. The ability of miR-21 expression to 
predict prognosis and its relationship to survival shown in our 
study and many other articles suggest its potential as a novel 
biomarker [3,4,16]. Although there were no significant differ-
ence between two groups regarding disease-free survival, pa-
tients with low miR-21 expression had better overall survival. 
This could reflect that disease progression after recurrence is 
worse in patients with high miR-21 expression, which may 
lead to other studies with new hypothesis. Numerous studies 
have demonstrated that the stability of miRNAs in formalin-
fixed paraffin embedded tissues is superior to that of mRNAs 
and data regarding the feasibility and reliability of miRNAs as 
markers in other body fluids are emerging [16,25-29]. In addi-
tion to this, Si et al. [8] showed in vitro inhibition of breast tumor 
cell growth by anti-miR-21 and inhibition of tumor growth in 
a xenograft carcinoma mouse model, suggesting the possibility 
of therapeutic use. Furthermore, Calin and Croce [6] proposed 
a theory that if miRNAs are inherited in the germline, abnor-
mal levels of expression of tumor-suppressor genes or onco-
genes will have an effect on cancer development. 
This study has several limitations. Although patient selection 
was consecutive from 2002 to 2004, lack of materials resulted 
in a small population for analysis and selection bias could have 
occurred. Because of the small population and short follow-
up period, the number of deaths was small, which could have 
influenced the analysis. In addition, there is currently no inter-
national standardized definition of methods of analysis and 
expression levels for miRNAs and some studies use mean value 
of RQ to define high and low expression while other studies 
have different definitions for grouping the expression level. This 
discordant analysis can lead to disagreement among studies.
In conclusion, our study shows that miR-21 is overexpressed 
in breast cancer and high expression shows association with 
poor prognostic factors and poor survival. These findings sug-
gest miR-21 to have profound potential as a marker to predict 
outcome, treatment response and as a method to treat breast 
cancer. To clarify the role of miR-21 and for its use as a bio-
marker and in targeting therapy, large worldwide population-
based studies with a standardized definition of miR-21 expres-
sion level are necessary. Moreover, researches relating miR-21 
with stem cells and heredity will bring advances of understand-
ing, treating and preventing breast cancers. 
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